2016
Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis
Smith PH, Weinberger AH, Zhang J, Emme E, Mazure CM, McKee SA. Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis. Nicotine & Tobacco Research 2016, 19: 273-281. PMID: 27613893, PMCID: PMC5939704, DOI: 10.1093/ntr/ntw144.Peer-Reviewed Original ResearchConceptsTransdermal nicotineSmoking cessationBupropion SRComparative efficacyFirst option treatmentSustained release bupropionPlacebo-controlled trialSex differencesCigarette smoking cessationNetwork Meta-AnalysisRelease bupropionCessation pharmacotherapyOption treatmentGeneral community sampleCigarette smokersQuit ratesVarenicline's efficacyPharmacological interventionsVareniclineBupropionNicotine addictionMeta-AnalysisPlaceboSimilar outcomesSignificant sex differences
2015
Systematic and Meta-Analytic Review of Research Examining the Impact of Menstrual Cycle Phase and Ovarian Hormones on Smoking and Cessation
Weinberger AH, Smith PH, Allen SS, Cosgrove KP, Saladin ME, Gray KM, Mazure CM, Wetherington CL, McKee SA. Systematic and Meta-Analytic Review of Research Examining the Impact of Menstrual Cycle Phase and Ovarian Hormones on Smoking and Cessation. Nicotine & Tobacco Research 2015, 17: 407-421. PMID: 25762750, PMCID: PMC4429881, DOI: 10.1093/ntr/ntu249.Peer-Reviewed Original ResearchConceptsMenstrual cycle phaseHormone levelsOvarian hormonesLuteal phaseSmoking behaviorSearch termsOvarian hormone levelsMenstrual phase effectsCessation-related behaviorsTiming of interventionNegative subjective effectsMenstrual cycle effectsProgesterone administrationFollicular phaseMedication responseQuit ratesTonic cravingInclusion criteriaMenstrual phaseNonsignificant trendSmoking outcomesCycle phaseSmokingSystematic reviewGreater tonicTargeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence
Verplaetse TL, Weinberger AH, Smith PH, Cosgrove KP, Mineur YS, Picciotto MR, Mazure CM, McKee SA. Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence. Nicotine & Tobacco Research 2015, 17: 486-495. PMID: 25762760, PMCID: PMC4432402, DOI: 10.1093/ntr/ntu280.Peer-Reviewed Original ResearchConceptsSmoking cessationNoradrenergic systemClinical evidenceTobacco dependenceNoradrenergic activityMedication developmentPoor smoking cessation outcomesCause of morbiditySmoking cessation outcomesStress reactivitySex-specific mechanismsLower quit ratesNicotine-related reinforcementCurrent medicationsMedication effectivenessNicotine reinforcementCessation outcomesNoradrenergic agentsQuit ratesTreatment strategiesTobacco useNoradrenergic compoundsSmoking outcomesTreatment developmentWomen
2014
Smoking and mental illness in the US population
Smith PH, Mazure CM, McKee SA. Smoking and mental illness in the US population. Tobacco Control 2014, 23: e147. PMID: 24727731, PMCID: PMC4201650, DOI: 10.1136/tobaccocontrol-2013-051466.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCross-Sectional StudiesDiagnostic and Statistical Manual of Mental DisordersFemaleHealth Status DisparitiesHumansLongitudinal StudiesMaleMental DisordersMental Health ServicesMiddle AgedPrevalenceSmokingSmoking CessationSocioeconomic FactorsTobacco Use DisorderYoung AdultConceptsPsychiatric diagnosisCessation ratesQuit ratesSpecific diagnosisMental health service useEstimates of smokingHealth service useCurrent psychiatric diagnosisSpecific psychiatric diagnosesNational Epidemiologic SurveyTimes greater oddsPast-year psychiatric diagnosisHeavy smokingPsychiatric comorbiditySmoking ratesTobacco useTreatment useComorbid disordersSmokingGreater prevalenceService useEpidemiologic SurveyGreater oddsCohort surveyUS population